Bluebird bio — EHA Data Review & ZYNTEGLO Approval Webcast (June 2019)
38 slides from Bluebird bio's conference presentation, Jun 14, 2019
Slide 1: EHA Data Review & ZYNTEGLO Approval Webcast
EHA Data Review & ZYNTEGLO® Approval Webcast June 14, 2019 Exhibit 99.1
Slide 2: Forward-looking statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: We Recode for Life
WE RECODE FOR LIFE Our ambition is to recode science, systems and the status quo, so lives can be lived fully.
Slide 4: Today's Agenda
Today’s Agenda SCD Data: HGB-206 Group C Dave Davidson, MD chief medical officer TDT Data: Northstar (HGB 204), Northstar-2 (HGB-207) and Northstar-3 (HGB-212) Dave Davidson, MD chief medical officer ZYNTEGLO® Launch Update Nick Leschly chief bluebird & Alison Finger chief commercial officer Q&A
Slide 5: Sickle Cell Disease (SCD) HGB-206 Group C
Sickle Cell Disease (SCD) HGB-206 Group C
Slide 6: Sickle Cell Disease
Sickle Cell Disease Severe blood disorder that causes anemia, frequent pain crises and shortened lifespan Global annual birth incidence ~ 300,000 – 400,000 Mean age of death in the U.S. is 44 years1 Bridgett’s Experience Diagnosed at 17 Had over 140 gallstones before diagnosis First transfusion at 1
Slide 7: HGB-206 Group C: Disposition
HGB-206 Group C: Disposition Currently enrolling *1 withdrew consent, 1 discontinued due to adverse event Definitions: HSCs, hematopoietic stem cells Currently Enrolled N=25 LentiGlobin Infused N=13 Median follow-up: 9.0 months (min – max: 1.0 – 15.2) Plerixafor Mobilization & Apheresis N=19 Discont
Slide 8: HGB-206 Group C: Patient characteristics
HGB-206 Group C: Patient characteristics N=19 patients who started cell collection Parameter Group C N=19 Age at consent, years median (min – max) 26 (18 – 36) Gender 8F 11 M Genotype, βS/βS 19 SCD History Hydroxyurea#, n 11 VOCs*, n Annualized no. of events, median (min – max) 15 4.0 (2.0 – 13.5) A
Slide 9: HGB-206 Group C: Median HbS ≤ 50% of total Hb
HGB-206 Group C: Median HbS ≤ 50% of total Hb in patients with ≥ 6 months of follow-up post LentiGlobin treatment Median Hb (g/dL) 10.7 11.5 11.4 11.7 15.0 36% 47% 33% 49% 59% 40% Definitions: % represent median Hb fractions as % of total; Hb, hemoglobin Data as of 7 March 2019 52% 46% 46% 50% Total
Slide 10: HGB-206 Group C: Decreased hemolysis following LentiGlobin treatment
HGB-206 Group C: Decreased hemolysis following LentiGlobin treatment Reticulocyte Counts Lactate Dehydrogenase Total Bilirubin Median (Q1, Q3) depicted; Dot-dash lines denote lower and upper limits of normal values; *Shows number of patients for whom data are available; † Total bilirubin at last fol
Slide 11: HGB-206 Group C: ≥70% of RBCs contain βA-T87Q by month 9
Proportion of Red Blood Cells (%) Data as of 7 March 2019 Definition: RBCs, red blood cells Mean is depicted - if N=1, data show technical replicates; *Pre-conditioning sample does not contain any βA-T87Q , signal represents false positives HGB-206 Group C: On average, ≥ 70% of RBCs from patients tr
Slide 12: HGB-206 Group C: Reduction in annualized rate of VOC plus ACS
HGB-206 Group C: Reduction in annualized rate of VOC plus ACS post treatment Definitions: ACS, acute chest syndrome; DP, drug product; VOCs, vaso-occlusive crises Investigator-reported adverse events of VOC or ACS are shown; *Patients with ≥ 1 VOC/ACS in the 2 years before Informed Consent; †Patient
Slide 13: HGB-206 Group C: Safety profile consistent with busulfan conditioning
HGB-206 Group C: Safety profile consistent with myeloablative busulfan conditioning Non-hematologic grade ≥ 3 AEs* Post DP infusion in ≥ 2 patients N=13 n (%) Febrile neutropenia 10 (77) Stomatitis 7 (54) Abdominal pain upper 2 (15) Alanine aminotransferase increased 2 (15) Blood bilirubin increased
Slide 14: Plans Based on Ongoing Engagement with Regulators
Plans Based on Ongoing Engagement with Regulators Ongoing Phase 1/2, single arm, multi-center, U.S. study N=41 (Group C) Primary Endpoint: HbAT87Q and Total Hb Key Secondary Endpoint: Reduction in severe VOEs ≥12 years of age - ≤50 years of age Phase 1/2, single-center in France N=7 (4 β-thalassemia
Slide 15: Transfusion-Dependent β-thalassemia (TDT)
Transfusion-Dependent β-thalassemia (TDT)
Slide 16: Conditional approval granted in EU for patients with TDT
Conditional approval granted in EU for patients with TDT and non-β0/β0 genotypes Gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte a
Slide 17: Northstar-2 median total hemoglobin and transfusion independence
Northstar-2: Median total hemoglobin at 6 months: 11.9g/dL; HbAT87Q was 9.5 g/dL (n=11) Gene therapy derived Hb (HbAT87Q) supports total Hb production soon after infusion All non- β0/β0 patients in Northstar (HGB- 204) and Northstar-2 who achieved TI, maintained TI Northstar: TI maintained up to 3.8
Slide 18: Broad clinical development program continues
Broad clinical development program continues Original manufacturing process All genotypes N=18 Refined manufacturing process Non-β0/β0 genotypes N=23 β0/β0 genotypes Refined manufacturing process N=15 HGB-204 Complete HGB-207 HGB-212 Original manufacturing process N=4 HGB-205 Complete
Slide 19: HGB-204: 8/10 non-β0/β0 patients achieved transfusion independence
HGB-204: 8/10 patients with non-β0/β0 genotypes achieved transfusion independence Definitions: Hb, hemoglobin; RBC, red blood cell; TI, transfusion independence (weighted average Hb ≥ 9 g/dL without RBC transfusions for ≥ 12 months) Median duration of TI: 38.0 months (min – max: 21.2 – 45.3 months);
Slide 20: HGB-204: 4/8 β0/β0 patients transfusion free for >12 months
HGB-204: 4/8 patients with β0/β0 genotypes have been transfusion free for > 12 months Hb (g/dL) At last study visit 9.1 9.8 8.6 10.9 3/8 patients with β0/β0 genotypes have achieved transfusion independence (weighted average Hb ≥ 9 g/dL without any red RBC transfusions for ≥ 12 months) Median duratio
Slide 21: HGB-204: Liver iron concentration decreased
HGB-204: Liver iron concentration decreased in patients who achieved transfusion independence Patients re-initiated iron chelation therapy a median of 13 months after LentiGlobin infusion (min – max: 2 – 15 months) Medians (min, max) depicted Definitions: LIC, liver iron concentration; M, month Data
Slide 22: HGB-207: Stable total Hb and HbAT87Q
HGB-207: Stable total Hb and gene therapy-derived HbAT87Q in 10/11 patients with ≥ 6 months follow-up #Last Hb before patient restarted red blood cell transfusions Definitions: Hb, hemoglobin Data as of 13 December 2018 Median Hb in patients free from transfusions at last study visit (g/dL) M6 (n=10
Slide 23: HGB-207: Total Hb in patients who stopped RBC transfusions
HGB-207: 8.8 – 13.3 g/dL total Hb in patients who have stopped RBC transfusions for ≥ 3 months (n=13) Data as of 13 December 2018 Hb (g/dL) at last visit 13.3 11.3 (transfused) 11.3 12.1 12.3 12.5 12.4 12.4 11.5 11.0 12.6 11.3 8.8 13.3 Transfusion status in patients with ≥ 3 months follow-up Patient
Slide 24: HGB-207: 4/5 evaluable patients achieved transfusion independence
HGB-207: 4/5 (80%) evaluable patients achieved the primary endpoint of transfusion independence Data as of 13 December 2018 Hb (g/dL) at last visit 13.3 11.3 (transfused) 11.3 12.1 12.3 12.5 12.4 12.4 11.5 11.0 12.6 11.4 8.8 13.3 Transfusion status in patients with ≥ 3 months follow-up Definitions:
Slide 25: HGB-212: Hb in patients off RBC transfusions ≥3 months
HGB-212: Hb of 10.2 – 13.6 g/dL in patients off RBC transfusions for ≥ 3 months (n=5) Hb (g/dL) At last assessment β0/β0 13.6 β0/IVS-I-110 10.5 IVS-I-110/IVS-I-110 11.5 IVS-I-110/IVS-I-110 8.6 β0/IVS-I-110 12.3 β0/β0 10.2 β0/β0 8.9 β0/β0 6.6 β0/β0 9.8 Time free from chronic transfusions in patients
Slide 26: HGB-212: HbAT87Q following treatment with LentiGlobin
HGB-212: HbAT87Q in patients following treatment with LentiGlobin Data as of 12 April 2019 Definition: Hb, hemoglobin All patients at month 6 have HbAT87Q ≥ 8 g/dL (n=4)
Slide 27: HGB-212: HbAT87Q contributes to total Hb
HGB-212: Gene therapy-derived HbAT87Q significantly contributes to Hb 59 – 91% of total Hb is HbAT87Q Hb fractions in patients with ≥ 3 month visit Data as of 12 April 2019 Genotype β0/β0 β0/ IVS-I-110 IVS-I-110/ IVS-I-110 β0/ IVS-I-110 IVS-I-110/ IVS-I-110 β0/β0 β0/β0 DP/Peripheral VCN 3.1/2.8 3.65
Slide 28: Clinical data supports desired outcomes in TDT & SCD
Clinical data supports patient and physician desired outcomes in TDT & SCD Phase 1/2 Up to 3.8 years of transfusion independence in Phase 1/2 (HGB-204) study in patients with TDT who do not have a β0/β0 genotype Phase 3 Total hemoglobin levels of 10.2 – 13.6 g/dL in patients who have β0/β0 genotype
Slide 29: Commercial launch update
Commercial launch update
Slide 30: A system not set up for one-time potentially curative treatments
A system NOT setup for one-time potentially curative treatments “The debate over price is fundamentally a debate over access. Gene therapies and other treatments that can cost millions of dollars can still be a relative bargain for what they give patients and society if they’re able to cure a diseas
Slide 31: Our commitment to recode the status quo
Our commitment to recode the status quo BLUE VALUE PRINCIPLES Focus on patient innovation and access Creative and disruptive Flexible and share risk Transparent, proud and proactive Don’t do silly short-sighted stuff Don’t truncate value because it’s a one-time potentially curative treatment Don’t p
Slide 32: Value-based payment over time based on outcome
FAIR VALUE RECOGNITION SHARED RISK HEALTH SYSTEM AFFORDABILITY PER PATIENT AFFORDABILITY OBJECTIVE STRATEGIC APPROACH Our approach – VALUE-BASED PAYMENT over time based on OUTCOME Lifetime cost-time effectiveness timeframe Base value only on patient QOL and Life Extension Pay ONLY IF the treatment w
Slide 33: Keeping it Focused on the Patient: Living with TDT
Keeping it Focused on the Patient: Living with TDT Potentially fatal genetic disease caused by mutations in the β-globin gene that result in reduced or absent hemoglobin Despite advances in iron management, TDT patients suffer from serious complications and organ damage caused by excess iron TDT pat
Slide 34: Assessing the value of ZYNTEGLO
What has (and has not) gone into assessing the value of ZYNTEGLO®? Quality of Life $4M $3M $2M $1M $0 Societal Value Life Extension Traditional All Inclusive Calculation Cost Offsets (U.S./EU Vary) (Returned To The System) Quality of Life $2M $1M $0 ZYNTEGLO Intrinsic Value $2.1M Benefit realized by
Slide 35: ZYNTEGLO Capped Payment Model - Europe
ZYNTEGLO CAPPED PAYMENT MODEL - EUROPE ZYNTEGLO® payment and pricing: value & outcome based, 5 year cap @ risk NO COST Potential Lifelong Benefit, 5 Years of Cost 5 4 3 2 1 Years A one-time treatment expected to deliver lifelong benefit with 5 years of cost versus continual, lifelong treatment and c
Slide 36: Next steps and launch readiness progress
What are next steps and how is launch readiness progressing? Each Journey is Different Country-by-Country Recoding Will Play Out Over Time EC Decision Team in place; completing set-up and working to activate QTCs Actively engaging payers Progressing forward with dossier submissions Working in collab
Slide 37: BLUE style commercial success factors
BLUE style commercial success factors Payment models may vary by country Focus on establishing the commercial model and operations for the long-term In the near-term, product revenue is not the most telling indicator on European TDT launch progress Performance metrics that we will be tracking and sh
Slide 38: Q & A
Q & A
bluebird bio — EHA Data Review & ZYNTEGLO Approval Webcast (June 2019) on 6ix